Month: 2025-06

HONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - With the national strategy of “new quality productive forces” driving high-quality development, Yee Hop Holdings Limited (“Yee Hop Holdings”; stock code: 1662.HK) subsidiary Absolute Pure EnviroSci Limited (“APEL” or “the Company”) is actively aligning with national policies. It has recently established a Microfactory in collaboration with the Hong Kong Productivity Council (“HKPC”) to industrialize the patented Wisepura Aquapura porous silica capsule technology in Hong Kong, promoting smart manufacturing and new industrialization. The HKPC’s Life & Health Tech Hall, which opened in March this year, showcases over 20 research achievements and innovative applications developed by the HKPC, InnoHK, local universities, and industry partners, including the patented Wisepura Aquapura porous silica capsule technology.The World’s First Wisepura Aquapura Microfactory Fully OperationalAs a significant achievement of the collaboration, the world’s first Wisepura Aquapura Microfactory, developed in collaboration between APEL and HKPC, was officially launched on 13 June 2025 in Kowloon Bay, Hong Kong. This marks the successful implementation of the first phase of “Industry 4.0” and a significant milestone in the industrialization of APEL’s research achievements. During the inauguration ceremony, attended by numerous guests from the investment and business sectors, Mr. Jackin Jim, Chairman of Yee Hop Holdings, Dr. David Chung, Chairman of APEL, and Dr. Pat Yeung, Director of APEL, jointly unveiled the Microfactory, officially announcing its commencement of operations.Dr. Pat Yeung, Director of APEL (first from the left), Mr. Jackin Jim, Chairman of Yee Hop Holdings (second from the left), Mr. Mohamed Butt, Executive Director of HKPC (second from the right), and Dr. David Chung, Chairman of APEL (first from the right) are pictured together at the Wisepura Aquapura Microfactory Inauguration Ceremony.Dr. David Chung, Chairman of APEL, said, “We are honored to collaborate with HKPC in establishing the Wisepura Aquapura Microfactory, and we would like to extend our heartfelt gratitude to HKPC for their support. This collaboration highlights our strong research and innovation capabilities in the field of life and health technology. The official commencement of production at the APEL Wisepura Aquapura Microfactory enhances our ability to meet the growing market demand and injects new momentum into the company’s development. Looking ahead, we will continue to expand our network of partners and actively pursue international opportunities, endeavoring to bring local research achievements to the global stage and contribute to global health and environmental protection, working together for a sustainable future.”Dr. David Chung, Chairman of APEL, delivers a speech at the inauguration ceremony.Establishes Strategic Partnership with Shanhu Group to Explore New Opportunities in Water Purification and Aquaculture Technology in the Greater Bay AreaGuangdong Shanhu Group Co., Ltd. (“Shanhu Group”), a global leader in indoor air environment solutions, has seen its core product, industrial fans, gain widespread popularity across six continents, serving over 50 million users. Since 2015, Shanhu Mechanical and Engineering Co., Ltd., a subsidiary of Shanhu Group, has taken a forward-looking approach in the research and development (R&D) of intelligent and energy-saving technologies for aquaculture machinery. On 13 June 2025, APEL officially signed a strategic Memorandum of Understanding (MoU) with Shanhu Group to jointly enter the water purification and intelligent aquaculture sectors. The collaboration aims to develop advanced solutions for high-demand applications such as water purification equipment, ecological restoration technologies, and smart monitoring systems. These innovations will target environmental projects including river remediation, black and odorous water treatment, and ecosystem rehabilitation. Additionally, the partnership will address the stable demand for new filtration materials, water treatment processes, and water quality monitoring technologies in municipal wastewater treatment plants and industrial park facilities. The two companies will also establish cooperative relationships with government environmental agencies and municipal engineering firms to participate in wastewater treatment project bids and provide customized solutions.The collaboration encompasses technological R&D, market expansion, and resource sharing. The two parties will jointly develop intelligent water quality monitoring systems, leveraging big data and artificial intelligence (AI) to optimize aquaculture decision-making while promoting high-efficiency purification technologies for environmental engineering and municipal wastewater treatment markets. The project will integrate Shanhu Group's expertise in electromechanical equipment and disinfection technologies with APEL's proprietary Wisepura Aquapura Microfactory water treatment solutions. This one-year agreement, renewable upon expiration, will initially focus on deploying the collaborative achievements in the Guangdong-Hong Kong-Macao Greater Bay Area through business and technical exchange forums. The partnership is expected to drive the advancement of environmental protection and aquaculture industries in the region, fostering industrial chain transformation. Looking ahead, the collaboration aims to gradually expand into overseas markets.APEL (left) and Shanhu Group sign a strategic Memorandum of Understanding.Advancing towards a new era of “Industry 4.0” with smart manufacturingIn advancing “Industry 4.0” initiative, the APEL Wisepura Aquapura Microfactory integrates cutting-edge technologies such as physical AI, the Internet of Things, and big data into its manufacturing processes. This enables smart monitoring and automated management, enhancing overall operational efficiency and product quality. To mitigate the impact of rapid temperature increase during mixing on the structural integrity and performance of the smart silica capsules, the factory has installed a customized smart temperature control system powered by physical AI to ensure stable product quality. The factory is also equipped with a human-machine interface (HMI), programmable logic controllers (PLCs), and clean-in-place (CIP) systems to boost production efficiency and flexibility. Additionally, it features an Industrial Internet of Things (IIoT) monitoring system to track change of temperature and volume and electricity usage in real time, optimizing energy management. It also adopts just-in-time (JIT) production management to reduce inventory backlog and resource waste, comprehensively promoting efficient smart manufacturing operations.By implementing lean management and the principles of smart manufacturing, APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization within a limited space. This achievement enables flexible small-batch customized production and achievies “Industry 4.0 1i Maturity,” paving the way for physical AI applications.Guests visiting the APEL Wisepura Aquapura Microfactory.Dual Advancement in Health and Environmental Technology InnovationWater is an essential resource for sustaining human life and ecological health. However, urban development has exacerbated water pollution, posing significant threats to public health and ecosystems. To address these challenges, APEL has developed Wisepura Aquapura, featuring the world’s first patented porous silica capsule technology. This innovation has received gold and silver medals at the International Exhibition of Inventions of Geneva in 2022 and 2024, respectively. It intelligently releases active ingredients upon contact with water, effectively eliminating over 95% of harmful microorganisms and antibiotic-resistant bacteria while also meeting diverse application needs. This technology has been widely applied across Hong Kong’s public infrastructure, targeting over 30 types of bacteria, fungi, and viruses in water supply, air conditioning, and sewage systems—including Legionella, hand-foot-and-mouth disease pathogens, influenza virus, and Candida albicans—significantly reducing the risk of waterborne and aerosol-transmitted diseases. Moreover, the silica capsule can be reused multiple times and safely disposed of at the end of its lifecycle, thereby minimizing environmental impact and setting a new standard for water treatment solutions.APEL’s world-first Wisepura Aquapura Microfactory successfully integrates customized production technology, mechanical automation, and data visualization, achieving “Industry 4.0 1i Maturity.”About Wisepura Aquapura MicrofactoryLocated in Kowloon Bay, the APEL Wisepura Aquapura Microfactory scales up laboratory processes to pilot production while effectively adapting to the spatial constraints of traditional multi-story industrial buildings in Hong Kong. It achieves a high production capacity of 6 tons per day. At the heart of the production line is its C-shaped layout, laying a solid foundation for efficient operations. The factory is equipped with mixing, filling, and screw capping systems, along with smart technologies, and a customized pipeline system that connects 5 pharmaceutical-grade mixing tanks, enabling comprehensive lean management. Due to the limited space, the factory is equipped with a 2.5-meter-high automatic capping machine that maximizes vertical space, demonstrating the perfect integration of space efficiency and smart technology.The launch of the Microfactory not only significantly enhances production efficiency but also accelerates APEL’s collaboration with Superpower Pumping Engineering Co., Ltd., facilitating the market expansion of research products. Furthermore, the Microfactory has received official orders from the Drainage Services Department, demonstrating strong recognition of its solutions and generating tangible economic benefits for the Company. To tap into the Japanese market, which places high value on personal health and environmental hygiene, APEL is currently holding an innovative interactive exhibition at The Lab. in Osaka to showcase its three flagship products—Wisepura water and air purification systems, GERMAGIC™ antimicrobial coating, and GERMAGIC™ PET health care solutions for pets—seizing growth opportunities in Asia’s health technology industry.About Yee Hop Holdings LimitedYee Hop Holdings Limited (stock code: 1662.HK) is a company listed on the Main Board of the Stock Exchange of Hong Kong Limited and a long established contractor in Hong Kong, principally engaged in the provision of foundation works and tunneling works. In addition, its associate company, Windmill Street Development, is engaged in the development of premium property projects in Birmingham, the United Kingdom. In 2023, the Group established Absolute Pure EnviroSci Limited (“APEL”), which focuses on health and environmental innovations, including the distribution and research and development of specialty biochemical and biomedical products. APEL has also established laboratories in collaboration with The Hong Kong University of Science and Technology (“HKUST”) and the Hong Kong Science Park successively. The joint laboratory, “HKUST-AP EnviroSci Ltd. Joint Laboratory on Health and Environmental Innovation,” was officially launched on 10 January 2024. Additionally, the “APEL Biomedical Technology Innovation and Translational Commercial Laboratory” located at the Hong Kong Science Park was officially inaugurated on 13 March 2024.For more information about Yee Hop Holdings, please visit: http://www.yee-hop.com.hk/About Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited (“APEL”), is an indirect non-wholly owned subsidiary of Yee Hop Holdings Limited, a company listed on the Main Board of the Stock Exchange of Hong Kong Limited (stock code: 1662.HK). With a mission to improve the quality of life and living environments, APEL is principally engaged in the research and development and commercialization of health and environmental innovations. Leveraging its Multilevel Antimicrobial Polymer (MAP-1) technology, APEL has developed specialized application formulas in four key areas: air purification in aircraft, water purification, livestock health, and eco-friendly building materials, all designed to address pressing global challenges. APEL looks forward to working with researchers and industry partners worldwide to drive further health and environmental innovations.For more information about APEL, please visit: https://apesl.com/For media inquiries, please contact:AJA (IR & Communications)Avy YuTel: +852 9500 4443Email: avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com.

KEY HIGHLIGHTS- Revenue up by 7.4% to HK$1,576.9 million- Profit from continuing operations rose by 43.1% to HK$300.8 million- Net gearing ratio down to 8.3% from 12.2%- Recommended Final Cash Dividend of HK5.50 Cents Per Share and Special Cash Dividend of HK6.00 Cents Per Share- Continued enrichment of pipeline through R&D and strategic in-licensing- Improved operational efficiency by enhancing capacity and optimizing production leverage efficiencyHONG KONG, Jun 13, 2025 - (ACN Newswire via SeaPRwire.com) - Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing, and sale of essential medicines and specialty drugs, today announced the annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2025 ("FY2025" or the "Reporting Period").Building on the growth momentum of previous years, Jacobson Pharma continued to make promising progress, achieving total revenue of approximately HK$1,576.9 million during the Reporting Period, a year-on-year growth of 7.4%. Profit for the year from continuing operations increased by 43.1% to HK$300.8 million, reflecting the Group’s steadfast commitment to strategic execution and operational excellence.The Group’s financial position remains strong, providing a solid foundation for fuelling future development and dividend returns to shareholders. Bolstered by a robust business performance and persistent cost management, the Group achieved an adjusted EBITDA of HK$572.8 million. Net gearing ratio improved to 8.3% from 12.2% at the close of FY2025, and cash reserves held steady at HK$509.0 million.The Board recommends the payment of a final cash dividend of HK5.50 cents per share (FY2024: HK3.00 cents per share) and a special cash dividend of HK6.00 cents per share (FY2024: Nil). Including the interim cash dividend of HK3.50 cents per share already paid, the total cash dividend for FY2025 would be HK15.00 cents per share (FY2024: HK5.50 cents per share), up by 172.7% year-on-year.Robust Portfolio Meets Rising Healthcare DemandThe Group’s sales growth in FY2025 was driven by multiple factors. Hong Kong’s extended flu season, compounded by circulating respiratory pathogens, led to a significant surge in demand for cold and flu treatments. Broader healthcare trends further supported this momentum, including an aging population, high rates of chronic conditions like diabetes and hypertension, and growing mental health needs. Additionally, public health initiatives heightened awareness of preventive care, reinforcing demand for medications and medical consultations. Together, these trends contributed to sustained sales momentum across the Group's businesses throughout the Reporting Period.The Group remains well-positioned to meet Hong Kong’s growing healthcare needs with its broad portfolio of essential medicines and specialty drugs. Backed by an efficient supply chain, it ensures reliable access to cost-effective treatment choices while reinforcing its role as a trusted healthcare service provider.Sustained R&D Momentum and Specialty Portfolio ExpansionMomentum in expanding the Group’s R&D pipeline of the Group was sustained throughout the Reporting Period, advancing its strategy to broaden the product portfolio. As of 31 March 2025, the pipeline comprised 219 products at various development stages.To expand its specialty drugs portfolio, the Group concluded various in-licensing agreements with global manufacturers for 20 high-performing products across key therapeutic areas such as immunology, oncology, cardiology, neurology, and rare diseases. Selected for their strong clinical profiles and market potential, these additions support sustained growth and reflect the Group’s commitment to advancing patient care through innovative therapies.Bringing Innovation to Enhance Patient OutcomesThe Group continues to expand market reach for Arsenic Trioxide Oral Solution, co-developed with The University of Hong Kong to treat acute promyelocytic leukaemia (APL). Clinical trials show a 97% survival rate and 100% molecular remission, earning it the Orphan Drug Designation from both the U.S. FDA and EMA. A global Phase III trial will be launched in 2026 with market approval targeted for 2028.Jacobson Pharma also achieved a significant milestone on 20 February 2025, with the launch of supply chain liaison services for Axicabtagene Ciloleucel (Yikaida) – a CAR-T therapy - in partnership with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Kairos Biotechnology Inc.. Supported by an Advanced Therapeutic Product (ATP) logistics license, this breakthrough therapy for diffuse large B-cell lymphoma marks a major advance in next-generation cancer care.Powering Growth with Smart ProductionIn line with the Groups’ strategic goal of enhancing its manufacturing capabilities, Jean Marie Pharmacal Co Limited, a member of the Group, commenced the development of a new pharmaceutical facility at Tai Po InnoPark in February 2025. Supported by the Hong Kong Government’s New Industrialisation Acceleration Scheme, the facility will house 10 smart production lines for sterile eye drops, solid dosage forms, and oral liquids. Leveraging AI, robotics, and real-time analytics, the advanced facility will boost production efficiency and quality standards. Trial production is slated for late 2026, with a focus on developing specialty products to cater to unmet medical needs. This investment strengthens the Group’s industry leadership and supports Hong Kong’s emergence as a hub for advanced pharmaceutical manufacturing.Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma, stated, “FY2025 has been another eventful year for Jacobson Pharma, underscoring the strength of our strategy, the dedication of our team, and the trust of our stakeholders. These foundations continue to position us as a leading force in Hong Kong’s generic pharmaceutical sector.Looking to 2026, we remain optimistic about our prospects and growth. Healthcare policy reforms and rising medication demand from an aging population and chronic conditions will fuel the growth of the generic drugs market. With a strong pipeline, expanding partnerships, and digital innovation, we are well-positioned to seize growth opportunities and create sustainable values for the Group’s businesses”About Jacobson Pharma Corporation Limited (Stock Code: 2633)Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated and engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 9 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.The Group is committed to strategically enhancing its portfolios by introducing high-value-added specialty products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan and Cambodia, forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website: http://www.jacobsonpharma.com Copyright 2025 ACN Newswire via SeaPRwire.com.

PIONEERTOWN, CA, June 13, 2025 - (ACN Newswire via SeaPRwire.com) - ESCAPE Records releases two transcendent works from its secretive Mojave Desert hub in Pioneertown CA: the Parallel Universe EP, a genre-defying musical odyssey from touring electronic artists and industry veterans, and Gong Song! (Live from Escape, Pioneertown CA), a 45-minute sound healing masterpiece by Alessandra Montana.Naturally Occurring Emoji - BEEPLEEveryday from BEEPLE. Cover of Parallel Universe EP. Courtesy of Escape Records LLC.Crafted where social media fades to the obscure and creativity thrives, these two new records aim to forge deep audience connections - inspiring a sense of solidarity between the creative and their audience.The Parallel Universe EP blends electronic, Americana, and Latin vibes, born during a songwriting retreat at ESCAPE's legendary studio, some 40 miles from the gates of Coachella in the high desert of California, a mile above sea level under a myriad of stars. Listeners are invited to ponder what their life would be like in a parallel universe; evoking poignant emotions in today's somewhat turbulent world.Tracks are shared by studio founder and producer ROC Gardner, Latin Grammy-nominated Cimafunk (La Vida), Jamie N Commons (Hold Me While You Wait), DJ Tennis (Life and Death), and Grammy-nominated Jan Blomqvist (Remote Control), joined by producers Joseph Ray (Nero), Daniel Cantisani, Nikko Gibler (RicoshÄ“i), and Devlin Thorn alongside artists that include Kim Bullard (Elton John) and Craig McClune (David Gray) who lent their expertise to evolving the tracks.Mixed by Mick Guzauski (Daft Punk, The Weeknd, Michael Jackson) and mastered by Bernie Grundman, tracks include Mezcalita (June 13), Happy Unhappy (June 20), La Sugar (June 27), and Never Know (July 4). BEEPLE's surreal artwork Naturally Occurring Emoji and an AI-driven video by The Dor Brothers amplify the EP's cosmic narrative."The universal sky we spent each night under sparked something raw," says ROC. "It was awesome breaking out of our channels - we got to capture all these ideas, unbound by trends or any other concerns - it was great fun!"Simultaneously, Alessandra Montana's Gong Song! (Live from Escape) captures a live 45-minute sound journey, recorded meticulously with vintage gear and microphones at ESCAPE. Guided by mixing engineer Rob Columbus and mastered by Grundman, Montana's gongs and sacred instruments weave a meditative portal for healing."Escape's magic let me share my practice globally. I can't wait for people to hear this and experience the journey we went on," says Montana.ESCAPE, a 140-acre creative haven hosting Rüfüs Du Sol, Arctic Monkeys, Usher, RAYE - and many others - fosters unfiltered artistry. The studio hopes to deliver magic - and its music - unfettered and unfiltered.Visit www.esca.pe for more.Assets: Press release, artwork, lyrics, .wav files available upon request.Interviews: info@esca.peJan Blomqvist appears courtesy of Armada Music B.V.Tracks:Mezcalita (1st Single): https://audiosalad.ffm.to/commons-roc-mezcalitaParallel Universe EP: https://audiosalad.ffm.to/parallel-universeGong Song! (Live from Escape): https://audiosalad.ffm.to/gong-songContact InformationSteven Bradley9/9 - Digital/Social Mediaescape@9slash9.comEscape RecordsLabel Contactinfo@esca.peSOURCE: Escape Records LLC Copyright 2025 ACN Newswire via SeaPRwire.com.

香港, 2025年6月13日 - (亞太商訊 via SeaPRwire.com) - 隨著國家「新質生產力」成為推動高質量發展的重要策略，義合控股有限公司（「義合控股」；香港主板上市編號：1662）旗下附屬公司 Absolute Pure EnviroSci Limited（「APEL」或「本公司」）積極響應國家政策，攜手香港生產力促進局（「生產力局」）共同建設智能微工廠，在香港實現 Wisepura Aquapura 多孔結構矽微囊專利技術產業化，推動香港智能製造和新型工業化。今年 3 月開幕的生產力局「生命健康科技館」展示了逾 20 項由生產力局、InnoHK 研發平台、本地大學及業界攜手研發的科技成果及創新應用，包括Wisepura Aquapura 多孔結構矽微囊專利技術。全球首個 Wisepura Aquapura 智能微工廠全面投入生產運營作為雙方合作的重要成果，APEL 與生產力局合作建設的全球首個 Wisepura Aquapura 智能微工廠於 2025 年 6 月 13 日香港九龍灣正式啟用，標誌著「工業 4.0」的第一階段正式落地和 APEL 科研成果產業化發展的重要里程碑。在投資界和商界眾多嘉賓的見證下，義合控股主席詹燕群先生、APEL 主席鍾偉强博士及 APEL 董事楊學光博士於啟用典禮上共同為 APEL Wisepura Aquapura 智能微工廠揭幕，正式宣告其投入生產運營。APEL 董事楊學光博士（左一）、義合控股主席詹燕群先生（左二）、生產力局總裁畢堅文先生（右二）及APEL 主席鍾偉强博士（右一）於 Wisepura Aquapura 智能微工廠啟用典禮合照。APEL 主席鍾偉强博士表示：「我們非常榮幸可以與生產力局合作建設 Wisepura Aquapura 智能微工廠，並衷心感謝生產力局對 APEL 的支持，充分印證了我們在生命健康科技領域深厚的科研實力與創新能力。APEL Wisepura Aquapura 智能微工廠的正式投產，提升了我們應對市場日益增長需求的能力，為公司發展注入新動能。展望未來，我們將持續拓展合作夥伴網絡，積極拓展國際版圖，致力將本地科研成果推向全球，為全球健康與環境保護貢獻力量，攜手共創可持續發展的美好未來。」APEL 主席鍾偉强博士於啟用典禮致辭。與山湖集團建立戰略合作關係，共拓大灣區水質淨化及水產養殖科技新機遇廣東山湖集團有限公司（「山湖集團」）作為全球領先的室內空氣環境處理專家，其核心産品大廈扇暢銷全球六大洲，服務超過5,000萬用戶。十年前，山湖集團旗下公司山湖機電前膽性地投入研發智能節能養殖機械科技。2025年6月13日，APEL與山湖集團正式簽署戰略合作備忘錄，共同進軍水質淨化治理及智能水産養殖領域。雙方計劃開發對水質淨化設備、生態修復技術、智能監測系統等有較大需求的包括各類環保工程項目，如河道治理、黑臭水體整治、生態修復等環保工程市場。對新型過濾材料、水處理工藝、水質監測技術等有穩定需求包括城市污水處理廠、工業園區污水處理設施的市政污水處理市場。與政府環保部門、市政工程公司建立合作關係，參與污水處理項目的招投標，提供定制化解决方案。合作內容涵蓋技術研發、市場拓展及資源共享。雙方將聯合開發智能水質監測系統，利用大數據及人工智能優化養殖決策，並針對環保工程、市政污水處理等市場推廣高效淨化技術。合作項目將深度融合山湖集團在機電設備與消毒技術的産業優勢，以及APEL旗下Wisepura Aquapura智能微工廠的先進水處理專利技術。此合作為期一年，期滿後可自動續約，通過雙方商業及技術資源技術交流會，合作成果將率先在粵港澳大灣區推廣應用，有望推動大灣區環保與水産養殖産業升級，帶動産業鏈的升級轉型，展望未來將逐步拓展至海外市場。APEL（左）與山湖集團簽署戰略合作備忘錄。邁向「工業4.0」智能製造新時代在推動「工業 4.0」的進程上，APEL Wisepura Aquapura 智能微工廠將人工智能、物聯網、大數據等先進技術整合到製造流程，實現智能監控與自動化管理，提升整體運營效率與產品品質。為解決混合過程中溫度急升對智能矽微囊結構和性能的影響，工廠安裝了一套由物理人工智能（Physical AI）驅動的定製智能溫控系統、工廠更配備人機介面（HMI）、可程式設計邏輯控制器（PLC）及在位清洗（CIP）系統，以提升生產效率與靈活性。此外，工廠引入工業物聯網（IIoT）監控系統，實時監測用電情況，有效優化能源管理；同時透過及時化生產管理（JIT）有效減少倉庫積壓及資源浪費，全面推動智能製造的高效運營。一眾嘉賓參觀 APEL Wisepura Aquapura 智能微工廠。健康與環境科技創新雙重升級水資源是維繫人類生命與生態環境健康的關鍵，但隨著城市發展，水污染問題日益嚴重，對公共衛生和生態系統構成重大威脅。為改善水質，APEL 研發的 Wisepura Aquapura 採用了全球首創、並於 2022 年及 2024 年榮獲日內瓦國際發明展一金一銀獎項的多孔結構矽微囊專利技術。該技術能在與水接觸時智能控釋其活性物質，有效消滅逾 95%的有害微生物及耐藥性細菌，同時滿足多樣化的應用需求。這項創新技術已廣泛應用於香港多個公共基礎設施，有效針對供水系統、空調系統及下水道系統中超過 30 種細菌、真菌及病毒，包括退伍軍人症、手足口病原體、流感病毒及白色念珠菌等，顯著減低水系統及氣溶膠傳播疾病的風險。此外，矽微囊系統可多次循環使用，且在使用壽命結束後亦能安全棄置，降低環境負擔，為水質處理解決方案樹立新標準。通過精益管理及智能製造的概念，APEL 全球首個 Wisepura Aquapura 智能微工廠在有限的空間內成功整合了定製的生產技術、機械自動化和數據可視化，實現靈活小批量定製生產和「工業 4.0 的 1i 成熟度水準」，為 Physical AI 的應用鋪平了道路。APEL 全球首個 Wisepura Aquapura 智能微工廠成功整合了定製的生產技術、機械自動化及數據可視化，實現了「工業 4.0的 1i 成熟度水準」。關於APEL Wisepura Aquapura 智能微工廠位於九龍灣的 APEL Wisepura Aquapura 智能微工廠將實驗室規模的工藝放大至中試規模，並巧妙適應香港傳統多層工業建築的空間限制，成功實現每日6噸的高效產能。生產線的核心在於其 C 形佈局設計，為高效運作奠定基礎。工廠配備混合系統、灌裝及旋蓋系統，以及智能化設置，並透過定製的管道系統連接 5 個藥用級混合罐，實現全流程精益管理。針對有限空間，工廠特別配備了一台 2.5米高的自動上蓋機，充分利用立面空間，展現空間利用與智能化的完美結合。智能微工廠的啟用和投產，不僅大幅提升了生產效率，也加速了 APEL 與力霸水泵機械工程有限公司的合作進程，促進科研產品的市場拓展。此外，智能微工廠已獲渠務署正式訂單，彰顯其解決方案獲得高度認可，並為公司持續帶來實質經濟效益。為佈局日本這個高度重視個人健康與環境衛生的市場，APEL 現正於大阪 The Lab.舉行創新互動展覽會，展示三大旗艦產品-Wisepura 水質及空氣淨化系統、GERMAGICTM 抗菌塗層和 GERMAGICTM PET 寵物健康及護理方案，把握亞洲健康科技產業的發展機遇。關於義合控股有限公司義合控股有限公司為香港主板上市公司（1662.HK），是香港一間歷史悠久的承建商，主要從事提供地基工程及隧道工程業務。此外，旗下聯營公司 Windmill Street Development 於英國伯明罕發展優質物業項目。集團於 2023 年成立 Absolute Pure EnviroSci Limited （「APEL」），主要從事健康及環境創新業務，包括特種生化及生物醫藥產品之分銷及研發業務，並先後與香港科技大學及香港科學園成立實驗室。其中「香港科技大學-AP EnviroSci Ltd.環境科學健康與環境創新聯合實驗室」之聯合實驗室於 2024 年 1 月 10 日啟用，而位於香港科學園之「APEL生物醫藥科技創新及轉化商業實驗室」亦於 2024 年 3 月 13 日正式啟用。欲知更多有關義合控股有限公司資料，請瀏覽網頁：http://www.yee-hop.com.hk/關於 Absolute Pure EnviroSci LimitedAbsolute Pure EnviroSci Limited（「APEL」）為香港聯合交易所主板上市公司-義合控股有限公司（香港主板上市編號：1662）的間接非全資附屬公司。以改善生活品質及居住環境為使命， APEL 主要從事健康與環境科技創新的研究、開發及商業化。基於其多層次殺菌塗層技術（MAP-1），APEL 已在四個關鍵領域：飛機空氣淨化、水質淨化、畜牧健康和環保建材，研發專門的應用配方，旨在應對全球迫切挑戰。APEL 期待與全球研究人員和行業夥伴合作，推動更多健康與環境科技創新。欲知更多有關 APEL 資料，請瀏覽網頁：https://apesl.com/傳媒如有查詢，請聯絡：AJA (IR & Communications)庾婉華電話：+852 9500 4443電郵：avy.yu@ajacapital.com.hk / info@ajacapital.com.hk Copyright 2025 亞太商訊 via SeaPRwire.com.

業績亮點- 收入增長7.4%至15.8億港元- 來自持續經營業務的溢利增長43.1％至3.0億港元- 淨資本負債比率由12.2％下降低至8.3％- 建議派發現金末期股息每股5.50港仙及現金特別股息每股6.00港仙- 持續通過研發及策略引進授權豐富產品線- 透過提高生產設施營運效率及槓桿，促進運營效率香港, 2025年6月13日 - (亞太商訊 via SeaPRwire.com) - 從事基礎藥物及專科藥物研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司（「雅各臣」或「公司」；股份代號：2633.HK）今天公佈公司及其附屬公司（統稱「集團」）截至二零二五年三月三十一日止年度（「二零二五財年」或「報告期」）的全年業績。承接過去數年的穩健增長勢頭，雅各臣於本財政年度持續錄得可觀表現，縱使面對持續的宏觀經濟挑戰，全年收入約為15.8億港元，按年增長7.4%。持續經營業務的溢利飆升43.1%，達至3.0港億元，充分體現集團堅守卓越營運及策略執行的成效。集團財務狀況保持強健，為推動未來發展及股息回報提供堅實基礎。在強勁業務表現及持續成本管理的支持下，集團於報告期內錄得經調整EBITDA約5.7億港元。淨資本負債比率由12.2％降至二零二五財年末的8.3％，現金儲備約為5.1億港元，維持穩定水平。董事會建議派付現金末期股息每股5.50港仙（二零二四年財年：每股3.00港仙）及現金特別股息每股6.00港仙（二零二四年財年：無）。包括已派付的現金中期股息每股3.50港仙，二零二五財年的現金股息合共每股15.00港仙（二零二四財年：每股5.50港仙），按年上升172.7％。多元產品組合滿足不斷上升的醫療需求集團於二零二五財年的銷售增長受多項因素推動。香港經歷漫長的流感季節，加上多種呼吸道病原體同時活躍，帶動對傷風感冒藥物的需求大幅上升。人口老化，加上糖尿病及高血壓等慢性疾病高發，以及精神健康需求日益增加等，進一步推升醫療需求的趨勢。此外，公共衛生計劃提高了公眾對預防保健及早治療的意識，增加對藥物和就診需求。在這些因素共同作用下，集團整體業務於報告期內維持銷售增長。憑藉豐富的基礎藥品及專科藥物組合，集團繼續具備優越的條件，滿足香港不斷增長的醫療需求，而透過高效的供應鏈，集團能夠提供具成本效益的治療選擇，進一步鞏固其作為香港值得信賴醫療服務供應商地位。持續推進研發與拓展專科藥物組合集團於報告期內持續推進研發管線擴充，貫徹產品組合拓展戰略。截至二零二五年三月三十一日，集團的研發項目包括219項處於不同開發階段的產品。為擴大專科藥物組合，集團與多家國際藥廠簽訂授權協議，引進20項高效藥物，涵蓋自身免疫性疾病、腫瘤、心血管疾病、神經疾病及罕見病等多個治療領域。這些新增藥物具有出色的臨床表現和市場潛力，不僅支持集團持續增長，更體現集團致力以創新療法改善患者生活質量的承諾。以創新科技提升治療成效集團持續擴大三氧化二砷口服液（Arsenol）的市場覆蓋，該產品用於治療急性早幼粒細胞白血病（APL），由集團與香港大學聯合開發。臨床試驗顯示，該療法的存活率為97%，分子學緩解達100%，因而獲美國食品藥品監督管理局及歐洲藥品管理局認定為罕見病用藥。全球第三期試驗將於二零二六年開始，目標是於二零二八年獲上市批准。集團亦於二零二五年二月二十日達成另一重大里程碑 - 與上海復星醫藥（集團）股份有限公司及Fosun Kairos Biotechnology Inc. 合作，推出CAR-T療法Axicabtagene Ciloleucel (商品名：Yikaida) 的供應鏈協調服務。此療法專為治療瀰漫性大B細胞淋巴瘤而設，並已獲發先進治療產品（ATP）物流牌照，標誌著集團在下一代癌症療法領域邁出重要一步。智能生產驅動產能為配合集團提升製造能力的策略目標，集團旗下公司正美藥品有限公司（Jean Marie Pharmacal Co. Limited）已於二零二五年二月於大埔創新園展開全新製藥設施的建設工作。在香港政府「新型工業加速計劃」的支持下，該廠房將配備十條智能生產線，用於生產無菌眼藥水、固體劑型藥物及口服液，通過AI、機器人及實時數據分析，提升生產效率及品質水平。試產計劃預計於二零二六年底展開，重點生產專科治療藥物，針對未被滿足的醫療需求。此項策略性投資不僅鞏固本集團的行業領導地位，更有助推動香港發展成為先進藥業製造樞紐。雅各臣主席及行政總裁岑廣業先生表示：「二零二五財年對雅各臣而言是充滿意義的一年，再次印證我們策略的前瞻性、團隊的堅毅與投入，以及持份者對我們的信任。這些堅實基礎，持續鞏固我們作為香港仿製藥市場領導者的地位。展望二零二六年，我們對業務前景充滿信心。隨着醫療政策改革推進，以及人口老化與慢性病帶動藥物需求上升，將持續推動基礎藥物市場增長。憑藉強大的產品線、不斷拓展的合作夥伴關係，以及數碼創新，我們已具備有利優勢，把握增長機遇，為集團業務創造可持續價值。」關於雅各臣科研製藥有限公司（股份代號：2633）雅各臣是本地領先的醫藥公司，擁有垂直整合的業務，包括基礎藥物及專科藥物的研發、生產、分銷、銷售及物流。作為本地主要的非專利藥供應商，集團在香港私營及公營領域，具有最廣泛的銷售及分銷的市場覆蓋，並積極向策略性選擇的亞洲市場伸延擴展。集團於香港設有9間PIC/S GMP認證的非專利藥生產設施，並在各種治療藥物類別中擁有廣泛的產品組合與享有優越市場地位。同時，集團一直致力透過增加各種高增值產品，策略性地擴大其非專利藥的產品組合。紮根香港，集團已於中國、澳門、台灣及柬埔寨開設營運子公司，建立區域性商業平台，以把握亞太區及大中華地區的市場潛力。而自 2017 年 6月 1 日，集團獲納入 MSCI 香港微型股指數成份股。更多詳情請瀏覽雅各臣科研製藥有限公司網站： http://www.jacobsonpharma.com Copyright 2025 亞太商訊 via SeaPRwire.com.

- 「創業快綫」終極決選10間優勝初創順利誕生，綠創能源有限公司奪得「環境、社會、企業管治大獎」，安神生物科技有限公司奪得「我最喜愛初創大獎」- 「創業快綫」終極決選日邀請到逾200名業界人士參與，助初創建立人脈及增加曝光，持續推動本港創業生態圈發展- 本屆優勝初創業務主要集中於健康科技，亦有多間來自綠色科技、智慧城市及人工智能等領域香港, 2025年6月13日 - (亞太商訊 via SeaPRwire.com) - 2025年6月12日，香港貿易發展局（香港貿發局）舉辦的第八屆初創培育計劃「創業快綫」終極決選順利完成，10間優勝初創誕生。大會今年繼續設有「環境、社會、企業管治大獎」(ESG Award)，表揚最具可持續發展及社會效益的初創企業，最終由綠創能源有限公司嬴得此獎項。至於現場觀眾一人一票選出的「我最喜愛初創大獎」，則由安神生物科技有限公司奪得。10間優勝初創將可參與一系列由貿發局組織的本地及海外的商貿活動，全面建人脈、拓市場、增曝光、覓夥伴。貿發局全力支援及推動初創企業發展，協助他們進軍海外及內地市場，推廣香港創科優勢。香港貿發局商品貿易及創新總監兼對外事務總監黃燕表示： 「『創業快綫』作為香港貿發局的旗艦初創培育計劃，一直推動本港最具潛力及創新的科技初創茁壯成長，致力協助本地初創提升實力及建立人脈，開拓新市場同時尋找商業及融資夥伴，並提升品牌知名度。自2018啟動計劃以來，我們已協助70間本地初創提升規模，同時擴展業務至海外市場，不少已取得卓越成就及贏得國際獎項，得到重大投資及建立重要的商業夥伴關係，充份體現這個平台加速推動香港初創成功發展。」第八屆「創業快綫」報名公司超過200間，反應踴躍。十間優勝初創業務主要集中於健康科技，亦有多間來自綠色科技、智慧城市及人工智能等領域。今年「創業快綫」終極決選日吸引逾200位業界人士參與，包括一眾投資者及商界領袖，現場亦設有初創展覽，由「創業快綫」入圍初創向與會人士進行業務介紹。貿發局將為優勝初創提供多元化商貿交流及配對活動晉身「創業快綫」最後20強的初創，在今天的終極決選上簡介業務及創業理念，在現場接受評判的即場提問及評分，最終勝出的10間優勝初創分別為：ACTuWISE Limited、Decennium Platforms Limited、安神生物科技有限公司、Digitoe Limited、世美拉有限公司、湯宏健康科技有限公司、Firefilm Group Limited、艾柏輪科技有限公司、Entoptica Limited及綠創能源有限公司。（請按此下載完整得獎名單及初創簡介）。香港貿發局將為優勝初創安排一系列的交流考察及推廣活動，與潛在投資者、買家和合作夥伴會面。評判讚賞優勝初創緊貼市場發展及決選表現評判之一阿里雲(亞太北區)資深顧問車品覺表示：「每屆新入選的初創都給我們帶來驚喜，面對AI迅速發展，不少企業都迅速將AI融入實體業務，可見本地初創人才緊貼市場趨勢，同時具備創新思維及一定實力。」另一評判香港初創企業協會主席杜偉樑亦表示：「本屆參賽初創質素頗高，提供的產品及服務牽涉不同科技領域，特別是在人工智能、綠色科技和醫療創新等方面。我們樂見新一代初創在創新及科技各範疇都持續推陳出新，為社會整體發展出一份力，展現出無限潛力和創造力。香港初創持續蓬勃增長，去年香港初創企業已達4,694間再創新高，顯示香港的營商吸引力有增無減，繼續是設立初創的理想地點，前景亮麗，相信今年的優勝初創將可透過『創業快綫』獲得更多拓展市場及建立人脈的寶貴發展機會。」「創業快綫」助初創取得公司投資及合作機會「創業快綫」為初創提供全面的宣傳機會，優勝初創企業將可親身參與內地及海外的展覽會，以及與本地及世界各地的投資者會面接洽等，從而了解更多行業動態、海外市場趨勢及投資者取向，以建立商脈和拓展市場及業務。上屆優勝初創之一途齡科技(Libpet Tech)最近更完成了300萬美元的種子輪融資，籌集所得資金將用於技術升級及拓展國際市場。途齡科技行政總裁徐華峰表示：「參加『創業快綫』成功為公司增加曝光及提升品牌知名度，獲得不少潛在客戶及投資者關注，在此十分感謝投資者對公司的信心。公司將攜手公私營合作夥伴，將機器人技術融入日常生活，推動以人為本的智慧出行。」第四屆「創業快綫：國際篇」12月舉行 全球初創大比拼香港貿發局一直致力加強本地與海外創業生態圈的交流，鞏固香港致力作為亞洲創科樞紐的競爭優勢。於2022年首度舉行的「創業快綫：國際篇」，過去三屆吸引環球各地如澳洲、法國、德國、日本、韓國、土耳其、新加坡、阿聯酋及美國等地的初創報名。第四屆「創業快綫：國際篇」今年將繼續在12月初的「創業日」舉行，協助勝出的海外初創落戶香港，並透過香港的平台探索大灣區及其他内地市場。「創業快綫」網頁：https://portal.hktdc.com/startupexpress/tc/圖片下載：http://bit.ly/4jPwedc10間「創業快綫」優勝初創企業順利誕生，得獎初創代表與評判及嘉賓一起合照。後排由左至右為：阿里雲（亞太北區）資深顧問車品覺、興迅集團主席兼董事總經理張益麟、道源資本集團首席執行官陳甄灝、香港貿發局商品貿易及創新總監兼對外事務總監黃燕、Betatron Venture Group管理合夥人兼執行長Matthias Knobloch、PRD初創投資主席湯雷、香港初創企業協會主席杜偉樑。「創業快綫」終極決選請來中小學生到場展示不同科創方案，由2023年優勝初創 Big Bang Academy 聯合創辦人唐蒨怡提供指導及頒發獎狀。「創業快綫」終極決選邀請逾200名業界人士參與，讓初創與投資者和商界領袖等一起交流。「創業快綫」終極決選現場設有初創展覽，入圍初創為與會者介紹公司業務。香港貿發局新聞中心：http://mediaroom.hktdc.com/tc傳媒查詢新聞界如有查詢，請聯絡香港貿發局傳訊及公共事務部：蘇顯博電話：(852) 2584 4049電郵：stanley.hp.so@hktdc.org黃家欣電話：(852) 2584 4524電郵：katy.ky.wong@hktdc.org張希汶電話：(852) 2584 4272電郵：serena.hm.cheung@hktdc.org劉茸電話：(852) 2584 4472電郵：clayton.y.lauw@hktdc.org香港貿易發展局簡介香港貿易發展局(香港貿發局)是於1966年成立的法定機構，負責促進、協助和發展香港貿易。香港貿發局在世界各地設有超過50個辦事處，其中13個設於中國內地，致力推廣本港作為雙向環球投資及商業樞紐。 香港貿發局通過舉辦國際展覽會、會議及商貿考察團，為企業(尤其是中小企)開拓內地和環球市場的機遇。香港貿發局亦通過研究報告和數碼資訊平台，提供最新的市場分析和產品資訊。有關香港貿發局的其他資訊，請瀏覽www.hktdc.com/aboutus/tc。 Copyright 2025 亞太商訊 via SeaPRwire.com.